Melanoma
From the Journals
Banning indoor tanning devices could save lives and money
Banning indoor tanning in the United States, Canada, and Europe could result in 187,481 fewer deaths from melanoma and save $5.7 billion.
From the Journals
Smartphone apps for suspicious skin lesions unreliable
"Regulators need to become alert to the potential harm that poorly performing algorithm-based diagnostic or risk monitoring apps create."
News
FDA: Cell phones still look safe
The available evidence does not suggest a causal link between cell phone use and cancer, according to the FDA.
From the Journals
Global project reveals cancer’s genomic playbook
The Pan-Cancer Analysis of Whole Genomes, an international collaboration, reveals the complexity of oncogenesis.
From the Journals
Circulating tumor cells at baseline predict recurrence in stage III melanoma
Patients with circulating tumor cells were three times more likely to have disease recurrence within 6 months.
From the Journals
Lenvatinib/pembrolizumab has good activity in advanced RCC, other solid tumors
Two-thirds of patients with advanced renal cell carcinoma had a clinical response to the TKI/immune checkpoint inhibitor combination.
From the Journals
Sharp declines for lung cancer, melanoma deaths fuel record drop in cancer mortality
Reductions in smoking are largely responsible for the lung cancer progress, while immunotherapy and targeted treatments have improved survival in...
From the Journals
New toxicity subscale measures QOL in cancer patients on checkpoint inhibitors
With further validation, the instrument could become an important tool for evaluation of treatment-related toxicity.
Conference Coverage
Combo elicits lasting responses in metastatic melanoma
NATIONAL HARBOR, MD. – In a phase 1/2 trial of previously untreated advanced melanoma patients, the combination of bempegaldesleukin and nivolumab...
From the Journals
Melanoma incidence drops in younger age groups
Fewer teens and young adults developed melanoma between 2006 and 2015, while incidence increased in older adults.
Conference Coverage
TLR9 agonist may overcome resistance to anti–PD-1 therapy in melanoma
NATIONAL HARBOR, MD. – CMP-001 plus pembrolizumab produced durable responses in patients who had progressed on prior...